Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.41 |
| ▸ | ITGAV | P06756 | 10/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GHSR | Q92847 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7148744 | 0.86 | HTR6 (0.43) | MAPTSMN1; SMN2ALDH1A1ADRB3 | |
| SCHEMBL4954940 | 0.83 | MAPT (0.42) | MAPTSMN1; SMN2ITGB3ITGAVKDM4E | |
| SCHEMBL7150473 | 0.83 | CASP3 (0.45) | MAPTALDH1A1L3MBTL1 | |
| SCHEMBL24106585 | 0.77 | ITGB3 (0.50) | MAPTSMN1; SMN2ITGB3ITGAVKDM4E | |
| SCHEMBL7147943 | 0.76 | MAPT (0.43) | MAPTSMN1; SMN2ITGB3ITGAVKDM4E | |
| SCHEMBL7785678 | 0.75 | ITGB3 (0.51) | MAPTSMN1; SMN2ITGB3ITGAVKDM4E | |
| SCHEMBL7785677 | 0.75 | ITGB3 (0.51) | MAPTSMN1; SMN2ITGB3ITGAVKDM4E | |
| SCHEMBL7787963 | 0.74 | ITGB3 (0.53) | MAPTSMN1; SMN2ITGB3ITGAVKDM4E | |
| SCHEMBL7787965 | 0.74 | ITGB3 (0.53) | MAPTSMN1; SMN2ITGB3ITGAVKDM4E | |
| SCHEMBL14186058 | 0.74 | MAPT (0.50) | MAPTSMN1; SMN2ITGB3ITGAVKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1347783-A1 | CONJUGATES OF INTEGRIN RECEPTOR ANTAGONISTS AND A CYTOSTATIC AGENT HAVING SPECIFICALLY CLEAVABLE LINKING UNITS | Bayer Aktiengesellschaft (DE) | 2003-10-01 | — | — | EP | disclosed |
| US-20020183256-A1 | Cytostatic-integrin conjugates having specifically cleavable linking units | BAYER AKTIENGESELLSCHAFT (DE) | 2002-12-05 | — | — | US | disclosed |
| EP-1238678-A1 | Enzyme-activated cytostatic conjugates with integrin ligands | Bayer Aktiengesellschaft (DE) | 2002-09-11 | — | — | EP | disclosed |
| WO-2002051444-A1 | CONJUGATES OF INTEGRIN RECEPTOR ANTAGONISTS AND A CYTOSTATIC AGENT HAVING SPECIFICALLY CLEAVABLE LINKING UNITS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-07-04 | — | — | WO | disclosed |
| EP-1219305-A1 | Conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units | Bayer Aktiengesellschaft (DE) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183256-A1 | Cytostatic-integrin conjugates having specifically cleavable linking units | ITGAV, ITGB3, ITGAL | MAPT 3777/4885SMN1; SMN2 2343/4885ITGB3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.